Skip to main content

Table 1 Baseline clinical characteristics

From: Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study

  Before propensity score matching After propensity score matching
NPR on clopidogrel (n = 1360) HPR on clopidogrel (n = 409) P Value NPR on clopidogrel (n = 395) HPR on clopidogrel (n = 395) P Value
Age, year 64.6 ± 10.2 66.9 ± 10.2 < 0.001 66.5 ± 9.8 66.7 ± 10.2 0.765
Male, n (%) 1028 (75.6) 289 (70.7) 0.045 264 (66.8) 278 (70.4) 0.283
BMI, kg/mm2 24.6 ± 2.9 25.1 ± 3.6 0.003 25.3 ± 3.1 25.0 ± 3.1 0.169
Hypertension, n (%) 949 (69.8) 311 (76.0) 0.014 298 (75.4) 305 (77.2) 0.558
Hyperlipidemia, n (%) 521 (38.3) 204 (49.9) < 0.001 198 (50.1) 200 (50.6) 0.887
Diabetes, n (%) 372 (27.4) 127 (31.1) 0.145 118 (29.9) 125 (31.6) 0.589
Current smoker, n (%) 511 (37.6) 132 (32.3) 0.051 137 (34.7) 131 (33.2) 0.652
ACS, n (%) 1226 (90.1) 361 (88.3) 0.272 359 (90.9) 349 (88.4) 0.243
eGFR ≥60 ml/min/1.73m2, n(%) 1205 (88.9) 359 (88.0) 0.625 339 (86.5) 347 (88.1) 0.503
Prior stroke, n (%) 18 (1.3) 15 (3.7) 0.005 5 (1.3) 12 (3.0) 0.086
Prior MI, n (%) 124 (9.1) 49 (12.0) 0.088 42 (10.6) 48 (12.2) 0.502
Prior PCI, n (%) 267 (19.6) 96 (23.5) 0.092 76 (19.2) 96 (24.3) 0.085
Prior CABG, n (%) 12 (0.9) 6 (1.5) 0.397 3 (0.8) 6 (1.5) 0.505
LVEF, % 59.7 ± 9.0 58.4 ± 8.2 0.488 58.5 ± 9.4 58.4 ± 8.2 0.952
Symptomatic HF, n (%) 222 (16.5) 79 (19.6) 0.155 97 (24.6) 79 (20.0) 0.124
Treatment at discharge
 Aspirin maintenance dose, n (%) 1360 (100) 408 (99.8) 0.231 395 (100) 394 (99.7) 0.317
 Clopidogrel maintenance dose of 75 mg, n (%) 1331 (97.9) 395 (96.6) 0.137 381 (96.5) 381 (96.5) NS
 Clopidogrel maintenance dose of 150 mg, n (%) 29 (2.1) 14 (3.4) 0.137 14 (3.5) 14 (3.5) NS
Treatment at last follow-up visit
 Aspirin maintenance dose, n (%) 1292 (95) 386 (94.4) 0.617 376 (95.2) 372 (94.2) 0.526
 Clopidogrel maintenance dose, n (%) 494 (36.3) 140 (34.2) 0.439 132 (33.4) 127 (32.2) 0.705
 Ticagrelor maintenance dose, n (%) 11 (0.8) 5 (1.2) 0.388 6 (1.5) 4 (1.0) 0.524
Laboratory
 Red blood cell, ×  1012/L 4.4 ± 0.6 4.6 ± 6.5 0.314 4.3 ± 0.6 4.6 ± 6.5 0.596
 Hemoglobin, g/L 133.7 ± 17.2 132.1 ± 55.3 0.436 132.0 ± 17.9 132.2 ± 55.8 0.973
 Platelet count, × 109/L 190.6 ± 66.9 190.3 ± 51.5 0.937 186.1 ± 55.5 189.9 ± 51.1 0.431
 hsCRP, ug/ml 32.1 ± 8.9 31.9 ± 8.8 0.858 31.8 ± 8.6 31.9 ± 8.9 0.883
  1. NPR normal platelet reactivity, HPR high platelet reactivity, BMI body mass index, ACS acute coronary syndrome, eGFR estimated glomerular filtration rate, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, LVEF left ventricular ejection fraction, HF heart failure, hsCRP high sensitivity C reactive protein